1448711-03-2Relevant academic research and scientific papers
C-4 modified sialosides enhance binding to Siglec-2 (CD22): Towards potent Siglec inhibitors for immunoglycotherapy
Kelm, S?rge,Madge, Paul,Islam, Tasneem,Bennett, Ryan,Koliwer-Brandl, Hendrik,Waespy, Mario,Von Itzstein, Mark,Haselhorst, Thomas
supporting information, p. 3616 - 3620 (2013/05/21)
Two changes for the better: A novel class of sialic acid derivatives is prepared by modifying both the C-4 and C-9 positions of Neu5Aα2Me (see structure). This approach gives a lead compound that has sub-micromolar affinity for Siglec-2 and may provide a pathway for immunoglycotherapy strategies for autoimmune diseases and B cell derived non-Hodgkin's lymphoma. Copyright
